DexCom (DXCM) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended September 2025, DexCom (DXCM) reported revenue of $1.21 billion, up 21.6% over the same period last year. EPS came in at $0.61, compared to $0.45 in the year-ago quarter.The reported revenue represents a surprise of +2.72% over the Zacks Consensus Estimate of $1.18 billion. With the consensus EPS estimate being $0.57, the EPS surprise was +7.02%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- United States: $851.9 million versus the six-analyst average estimate of $843.25 million. The reported number represents a year-over-year change of +21.4%.Revenue- International: $357.4 million versus the six-analyst average estimate of $332.15 million. The reported number represents a year-over-year change of +22.3%.Revenue- Hardware: $34.2 million compared to the $39.65 million average estimate based on three analysts. The reported number represents a change of -19.3% year over year.Revenue- Sensor and other: $1.18 billion versus $1.14 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +23.5% change.View all Key Company Metrics for DexCom here>>>Shares of DexCom have returned +3.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks